Q2 EPS Estimates for Editas Medicine Decreased by Analyst

Key Points

• Zacks Research lowered its Q2 2026 EPS estimate for Editas to ($0.34) from ($0.33), and now models FY2026 EPS at ($1.38) and FY2027 EPS at ($1.36).
• Editas unexpectedly beat last quarter's expectations, reporting EPS of ($0.06) versus a consensus of ($0.27) and revenue of $24.74 million versus estimates of $8.77 million.
• Shares opened at $2.25 (down ~6.3%), the company has a market cap of about $220 million, and analysts hold a consensus Moderate Buy rating with an average price target of $5.30.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for shares of Editas Medicine in a report released on Monday, March 23rd. Zacks Research analyst Team now expects that the company will earn ($0.34) per share for the quarter, down from their prior estimate of ($0.33). The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine's Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.36) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.21. The firm had revenue of $24.74 million for the quarter, compared to analyst estimates of $8.77 million. Editas Medicine had a negative net margin of 395.02% and a negative return on equity of 389.73%.

EDIT has been the topic of several other reports. Chardan Capital reaffirmed a "buy" rating and issued a $3.50 price objective on shares of Editas Medicine in a research report on Monday, March 9th. TD Cowen reiterated a "buy" rating on shares of Editas Medicine in a report on Monday, March 9th. Weiss Ratings reissued a "sell (e+)" rating on shares of Editas Medicine in a research note on Wednesday, January 21st. JonesTrading upgraded Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 price target on the stock in a report on Tuesday, March 10th. Finally, Robert W. Baird set a $6.00 price objective on Editas Medicine in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $5.30.

Editas Medicine Stock Down 6.3%

Shares of EDIT stock opened at $2.25 on Wednesday. Editas Medicine has a 12-month low of $0.91 and a 12-month high of $4.54. The firm has a fifty day moving average of $2.09 and a 200-day moving average of $2.56. The company has a market capitalization of $220.21 million, a price-to-earnings ratio of -1.19 and a beta of 2.16.

Hedge Funds Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of EDIT. Captrust Financial Advisors bought a new stake in Editas Medicine in the second quarter valued at approximately $26,000. StoneX Group Inc. bought a new position in shares of Editas Medicine during the 4th quarter worth approximately $33,000. Victory Capital Management Inc. bought a new position in shares of Editas Medicine during the 3rd quarter worth approximately $36,000. Sei Investments Co. acquired a new position in shares of Editas Medicine during the 3rd quarter worth approximately $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Editas Medicine during the 3rd quarter worth approximately $50,000. Institutional investors own 71.90% of the company's stock.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.